title: [Ocular wavefront aberrations in patients with facial dystonia treated with botulinum toxin].
abstract: OBJECTIVE
  To analyze the ocular wavefront aberrations in patients with facial dystonia treated with botulinum toxin A.
  
  
  METHODS
  Patients with benign essential blepharospasm and hemifacial spasm in activity underwent slit lamp examination and bilateral wavefront analysis under pharmacologic mydriasis using Alcon LADARvision wavefront aberrometry system. After that, all patients were treated with botulinum toxin A injections performed by the same ophthalmologist. After one month, the wavefront analysis was performed in the same way and by the same examiner. The main outcome measure was the change in ocular wavefront aberrations. Paired T-test was used to compare pre and post-injection numeric wavefront values.
  
  
  RESULTS
  From a total of 11 patients enrolled in this study, 6 (54.5%) had essential blepharospasm and 5 (45.5%) had hemifacial spasm. The fellow eyes of patients with hemifacial spasm were not included, totalizing 17 eyes with spasm. Eight patients were female (72.7%) and three were male (27.3%), the male:female ratio was 1:2.6. The age ranged from 50 to 72 years old with a mean of 65.9 ± 8.2 years. The mean of high order root mean square (RMS) wavefront aberrations was 0.68 before and 0.63 one month after the treatment (p=0.01). Before the treatment, the mean of spherical aberration was 0.23 and decreased to 0.17 one month after the treatment (p=0.01). There was no significant difference in the other higher-order aberrations before and after the treatment (p>0.05).
  
  
  CONCLUSIONS
  The treatment with botulium toxin may decrease spherical aberrations in patients with facial dystonia.
authors.affiliation: Departamento de Oftalmologia, Universidade Federal de São Paulo - UNIFESP - São Paulo (SP), Brazil.
authors.forename: Mariann Midori
authors.initials: MM
authors.lastname: Yabiku
authors.forename: Juliana de Filippi
authors.initials: Jde F
authors.lastname: Sartori
authors.forename: Eduardo Pantaleão
authors.initials: EP
authors.lastname: Sarraff
authors.forename: Tammy Hentona
authors.initials: TH
authors.lastname: Osaki
authors.forename: Sidarta Keizo
authors.initials: SK
authors.lastname: Hossaka
authors.forename: Carolina Isolane
authors.initials: CI
authors.lastname: Pereira
authors.forename: Wilson de
authors.initials: Wd
authors.lastname: Freitas
authors.forename: Midori Hentona
authors.initials: MH
authors.lastname: Osaki
authors.forename: Angelino Julio
authors.initials: AJ
authors.lastname: Cariello
mesh_terms: D000368:Aged; D001764:Blepharospasm / Q000188:drug therapy* / Q000503:physiopathology; D019274:Botulinum Toxins, Type A / Q000627:therapeutic use*; D057108:Corneal Wavefront Aberration / Q000188:drug therapy*; D004421:Dystonia / Q000188:drug therapy* / Q000503:physiopathology; D005260:Female; D019569:Hemifacial Spasm / Q000188:drug therapy* / Q000503:physiopathology; D006801:Humans; D008297:Male; D008875:Middle Aged; D009465:Neuromuscular Agents / Q000627:therapeutic use*; D016896:Treatment Outcome
chemical_list: D009465:Neuromuscular Agents; D019274:Botulinum Toxins, Type A